Qiagen (NYSE:QGEN) Rating Lowered to “Hold” at Wall Street Zen

Qiagen (NYSE:QGEN) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Saturday.

Several other research firms have also commented on QGEN. Weiss Ratings restated a “hold (c)” rating on shares of Qiagen in a research report on Monday, December 8th. Barclays set a $53.00 target price on shares of Qiagen and gave the company an “overweight” rating in a research note on Thursday, October 2nd. Finally, Citigroup lowered shares of Qiagen from a “buy” rating to a “neutral” rating and dropped their price target for the company from $55.00 to $50.00 in a research note on Thursday. Two research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat, Qiagen has an average rating of “Hold” and a consensus target price of $49.28.

Qiagen Stock Down 0.4%

Shares of Qiagen stock opened at $45.25 on Friday. The stock has a market capitalization of $10.06 billion, a price-to-earnings ratio of 24.59, a PEG ratio of 2.31 and a beta of 0.67. Qiagen has a twelve month low of $37.63 and a twelve month high of $51.88. The company has a current ratio of 2.60, a quick ratio of 2.30 and a debt-to-equity ratio of 0.45. The business’s 50 day simple moving average is $46.50 and its 200-day simple moving average is $47.13.

Qiagen (NYSE:QGEN) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.03. Qiagen had a return on equity of 14.80% and a net margin of 19.58%.The business had revenue of $532.58 million during the quarter, compared to analyst estimates of $525.68 million. During the same quarter in the previous year, the firm posted $0.57 EPS. The business’s revenue for the quarter was up 6.2% compared to the same quarter last year. Equities research analysts forecast that Qiagen will post 2.26 earnings per share for the current year.

Hedge Funds Weigh In On Qiagen

A number of institutional investors and hedge funds have recently bought and sold shares of QGEN. SVB Wealth LLC bought a new position in shares of Qiagen in the first quarter valued at approximately $31,000. Danske Bank A S acquired a new stake in Qiagen in the third quarter worth approximately $36,000. Smartleaf Asset Management LLC boosted its stake in Qiagen by 1,383.3% during the 3rd quarter. Smartleaf Asset Management LLC now owns 890 shares of the company’s stock valued at $39,000 after purchasing an additional 830 shares in the last quarter. MAI Capital Management increased its position in shares of Qiagen by 998.9% during the 2nd quarter. MAI Capital Management now owns 978 shares of the company’s stock valued at $47,000 after purchasing an additional 889 shares during the period. Finally, Farther Finance Advisors LLC increased its position in shares of Qiagen by 400.5% during the 2nd quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company’s stock valued at $51,000 after purchasing an additional 849 shares during the period. Institutional investors own 70.00% of the company’s stock.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.